Archive for December 2009
Is Calcineurin activity useful as a biomarker to optimize cyclosporine a therapy in renal transplant recipients?
Press R.R., Rossum H.H. v., Ploeger B.A., Hartigh J.d., Pelt J.v., Guchelaar H.J., Fijter J.W.d. and Danhof M., Is Calcineurin activity useful as a biomarker to optimize cyclosporine a therapy in renal transplant recipients? PAGE.(2009).[Link to publication]
Read MoreTowards the implementation of the Markov property into a continuous-time transition state model in NONMEM
Snelder N., Diack C., Benson N., Ploeger B.and Graaf P.v.d., Towards the implementation of the Markov property into a continuous-time transition state model in NONMEM. PAGE.(2009). [Link to publication]
Read MoreModelling non-linear dose-dependent absorption profiles after oral prolonged release formulations
Liefaard L., Huntjens D., Vermeulen A. and Drenth H., Modelling non-linear dose-dependent absorption profiles after oral prolonged release formulations. PAGE.(2009).[Link to publication]
Read MoreSafety pharmacology screening using a standardized population pharmacokineticpharmacodynamic modelling approach
Snelder N., Steeg T.v., Ploeger B., Atkins N. and Graaf P.v.d., Safety pharmacology screening using a standardized population pharmacokineticpharmacodynamic modelling approach. PAGE.(2009). [Link to publication]
Read MoreGenotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar
Stringer F., Ploeger B., Jongh J.d., Scott G., Urquart R., Karim A. and Danhof M., Genotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar PAGE.(2009). [Link to publication]
Read MorePharmacokinetic and pharmacodynamic modeling of the novel oral direct factor Xa inhibitor TAK-442
Stringer F., Ploeger B., Scott G., Kawamura M. and Kupfer S., Pharmacokinetic and pharmacodynamic modeling of the novel oral direct factor Xa inhibitor TAK-442. ASCPT (2009).
Read MorePharmacokinetics of amoxicillin
Muller A.E., Oostvogel P.M., Jongh J.d., Mouton J.W., Steegers E.A., Dorr P.J., Danhof M. and Voskuyl R.A., Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera, Antimicrob Agents Chemother, 53(4): 1574-1580, 2009. [Link to publication]
Read MoreMorphine glucuronidation
Knibbe C.A., Krekels E.H., Anker J.N.v.d., Jongh J.d., Santen G.W., Dijk M.v., Simons S.H., Lingen R.A.v., Jacqz-Aigrain E.M., Danhof M. and Tibboel D., Morphine glucuronidation in preterm neonates, infants and children younger than 3 years, Clin Pharmacokinet, 48(6): 371-385, 2009. [Link to publication]
Read MorePopulation pharmacokinetic model of the pregabalin-sildenafil interaction in rats
Bender G., Gosset J., Florian J., Tan K., Field M., Marshall S., Jongh J.d., Bies R. and Danhof M., Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design, Pharm Res, 26(10): 2259-2269, 2009. [Link to publication]
Read MorePharmacokinetics of a granisetron transdermal system
Howell J., Smeets J., Drenth H.J. and Gill D., Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy- induced nausea and vomiting, J Oncol Pharm Pract, 20: 20, 2009. [Link to publication]
Read More